Phillips-Medisize, a subsidiary of the Molex company, will now offer market-ready, pre-filled pen injectors that are capable of delivering novel and generic drug treatments. The company states that the pen injectors are suited for high-volume manufacturing, and that the pen is more affordable to produce compared to similar drug delivery devices.
The pen injector has been designed to match user expectation and experiences with disposable pen products, the company added.
One differentiation is that the pen has been created to be smaller than most comparable products on the market. Phillips-Medisize describes the pen as being 150mm in length and with a diameter of 17mm. The pen accepts cartridge sizes of 3ml and 1.5ml.
Diabetes, fertility, obesity
The pen features customizable dosing, as well as push-button colors to signal different dosing and drug requirement for various therapies. Phillips-Medisize states that the pen injector is suitable for diabetes, fertility, obesity, and osteoporosis treatments, as well as growth hormones.
The company has created sample devices to support technical evaluation and human factors studies, while clinical devices are scheduled to be ready for the end of 2023.
“A pen injector is an important addition to Phillips-Medisize's expanding product and platform portfolio that empowers Biopharma companies to accelerate the rollout of novel and generic drug treatments at significant economies of scale,” said Paul Chaffin, president of medical and pharmaceutical solutions, Molex.
End to end capabilities
The pen injector joins the company’s Aria smart autoinjector product within its product portfolio. This device is a handheld system that has a reusable electro-mechanical injector and a pre-filled disposable syringe. The device also possesses Bluetooth connectivity, to help healthcare professionals provide patient support.
The devices are manufactured out of the company’s manufacturing network, which features 32 facilities across 11 countries. Phillips-Medisize stated that these sites are capable of complex molding, drug and reagent handling, final packaging and serialization. This allows the company to provide end-to-end capabilities to its clients.
In 2021, the company announced a major expansion of its manufacturing capabilities through creating a new facility in Poland, and through the expansion of existing facilities in China and the US. At the time, Phillips-Medisize outlined that this would bring the total manufacturing space present within its network to nearly 3 million-square-feet.
Outside of designing its own drug delivery devices, the company also offers collaboration services that involve product design, development, manufacturing, and post-launch services.
